echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Is Tebipenem Pivoxil Hydrobromide's efficacy in the treatment of complex urinary tract infections inferior to intravenous ertapenem? - Cutting-edge research

    Is Tebipenem Pivoxil Hydrobromide's efficacy in the treatment of complex urinary tract infections inferior to intravenous ertapenem? - Cutting-edge research

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Complicated urinary tract infection refers to the presence of acquired infection at the same time as the occurrence of urinary tract infection, or the failure of urinary tract infection treatment caused by structural and functional abnormalities such as bladder and ureter, which is likely to cause progressive decline in renal function due to repeated recurrence, which requires great attention



    Tebipenem Pivoxil Hydrobromide is an oral bioavailable carbapenem antibiotic with activity against urinary tract pathogenic Enterobacter, including ultra-broad-spectrum β-lactamase and fluoroquinolone-resistant strains




    In this international, double-blind, double-mock trial, patients were randomly assigned oral Tebipenem Pivoxil Hydrobromide (600 mg/8 hours) or intravenous ertapenem (1 g/24 hours) on a 1:1 ratio for 7 to 10 days (up to 14 days in patients with bacteremia).




    A total of 1372 hospitalized adult patients were included, of which 868 (63.



    efficacy


    At THE TOC visit, the overall response rate of oral Tebipenem Pivoxil Hydrobromide was no less than that of intravenous ertapenem (58.



    Table 1 Evaluation of efficacy of two sets of trials (number percentage shown)

     

    At the TOC visit, similar microbiological responses were observed in the enterobacter pathogens in both treatment groups, and the TOC response rates of E.



    security

    The Tebipenem Pivoxil Hydrobromide and Enthapenem groups had 1 case (0.
    1%) and 8 cases (1.
    2%) of adverse events (AE)
    of premature discontinuation of the test drug in the Tebipenem Pivoxil Hydrobromide and enthapenem groups, respectively.

    Nine (1.
    3%) and 12 (1.
    7%) patients in both groups had at least one serious adverse event (SAE) (Table 2
    ).

    The overall incidence of AE in both groups was 25.
    7% and 25.
    6%, respectively, with more than 1% of patients reporting AE as diarrhea, headache, and nausea, and most AE being mild or moderate in severity and non-therapeutic limitation
    .

    Table 2 Incidence of adverse reactions during the trial period

     


    conclusion

    Oral Tebipenem Pivoxil Hydrobromide is no less effective than intravenous ertapenem in patients with complicated urinary tract infection or acute pyelonephritis and has a similar safety profile
    .

    References:

    1.
    Meng Xianfeng,Zhang Zhe.
    Research progress in the treatment of complicated urinary tract infections in traditional Chinese medicine[J].
    Electronic Journal of Cardiovascular Diseases in Integrated Traditional Chinese and Western Medicine,2019,7(33):10+19.

    2.
    Eckburg PB, Muir L, Critchley IA, et al.
    Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
    N Engl J Med.
    2022 Apr 7; 386(14):1327-1338.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.